Home › Funds › Soleus Capital Management, L.P. › IKT
Soleus Capital Management, L.P. position in IKT
INHIBIKASE THERAPEUTICS INC · Health Care
Soleus Capital Management, L.P. reported holding 10,875,000 shares of IKT (INHIBIKASE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$22.1M, representing 0.76% of its reported portfolio and ranking #37 among its reported holdings. Soleus Capital Management, L.P. has disclosed IKT holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Soleus Capital Management, L.P.'s IKT position evolved
Soleus Capital Management, L.P. first disclosed a stake in IKT in Q4 2024 at 6,325,000 shares (US$20.6M). The position peaked in Q4 2025 at 10,875,000 shares, worth US$22.3M. Across 7 filings, Soleus Capital Management, L.P. increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 5 time(s). The most recent filing (Q2 2026) shows 10,875,000 shares valued at US$22.1M. Notable position changes include a 72% increase in Q4 2025 (shares fell 18% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 6.33M | $20.56M | New |
| Q1 2025 | 6.33M | $13.85M | Hold |
| Q2 2025 | 6.33M | $12.33M | Hold |
| Q3 2025 | 6.33M | $10.25M | Hold |
| Q4 2025 | 10.88M | $22.29M | Add |
| Q1 2026 | 10.88M | $18.27M | Hold |
| Q2 2026 | 10.88M | $22.08M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About IKT and 13F data
IKT (INHIBIKASE THERAPEUTICS INC) is a Health Care company. 69 other funds we track also report a position in IKT — the largest reported positions include Sands Capital Alternatives, LLC (US$26.4M), Trails Edge Capital Partners, LP (US$18.4M), Fairmount Funds Management LLC (US$17.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding IKT
- Sands Capital Alternatives, LLC 13.02M sh · $26.43M · Q2 2026
- Trails Edge Capital Partners, LP 9.05M sh · $18.37M · Q2 2026
- Fairmount Funds Management LLC 8.62M sh · $17.51M · Q2 2026
- ADAR1 Capital Management, LLC 7.39M sh · $15.00M · Q2 2026
- Commodore Capital LP 5.40M sh · $10.96M · Q2 2026
- Saturn V Capital Management LP 3.87M sh · $7.85M · Q2 2026
- Kalehua Capital Management LLC 3.82M sh · $7.76M · Q2 2026
- Spruce Street Capital LP 3.58M sh · $7.27M · Q2 2026
- Squadron Capital Management LLC 3.00M sh · $6.09M · Q2 2026
- Stonepine Capital Management, LLC 396.18K sh · $804.24K · Q2 2026
More on Soleus Capital Management, L.P.
FAQ
How long has Soleus Capital Management, L.P. held IKT?
Soleus Capital Management, L.P. has disclosed IKT holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is Soleus Capital Management, L.P.'s current position in IKT?
As of Q2 2026, Soleus Capital Management, L.P. holds 10.88M shares of IKT (INHIBIKASE THERAPEUTICS INC), valued at $22.08M, representing 0.76% of its reported portfolio and ranking #37.
Has Soleus Capital Management, L.P. been buying or selling IKT?
In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. held unchanged its position in IKT. The position peaked in Q4 2025 at 10.88M shares.
Which other funds hold IKT?
Other major institutional holders of IKT include Sands Capital Alternatives, LLC, Trails Edge Capital Partners, LP, Fairmount Funds Management LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.